Shanghai Synvida Biotechnology Co.,ltd.
Clinical trials sponsored by Shanghai Synvida Biotechnology Co.,ltd., explained in plain language.
-
New drug SV001 aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis study tests a new drug, SV001, in 48 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either SV001 or a placeb…
Phase: PHASE2 • Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Healthy volunteers test new drug SV003 for safety
Knowledge-focused Recruiting nowThis early-phase study tests the safety and how the body handles a new drug called SV003 in 60 healthy adults. Participants receive a single dose of either SV003 or a placebo. The goal is to check for side effects and measure drug levels in the blood, not to treat any disease.
Phase: PHASE1 • Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 08:03 UTC
-
Healthy volunteers test First-in-Human drug for lung scarring
Knowledge-focused Recruiting nowThis early-stage study tests a new drug, SV001, in 53 healthy Chinese adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a serious lung-scarring disease. This trial does not involve patients with the disease a…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 07:59 UTC